Taiho Oncology, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2002-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.taihooncology.com
Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
- First Posted Date
- 2014-05-08
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02134067
- Locations
- 🇺🇸
University of Colorado Hospital Anschutz Cancer Pavilion, Aurora, Colorado, United States
🇺🇸Washington University School of Medicine Division of Oncology Siteman Cancer Center, Saint Louis, Missouri, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
A Study of TAS-120 in Patients With Advanced Solid Tumors
- First Posted Date
- 2014-02-03
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 407
- Registration Number
- NCT02052778
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Virginia Mason Cancer Center, Seattle, Washington, United States
Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT02031055
- Locations
- 🇺🇸
University of Pittsbutgh Cancer Institute, Pittsburgh, Pennsylvania, United States
A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors
- First Posted Date
- 2014-01-01
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT02025803
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸IU Simon Cancer Center, Indianapolis, Indiana, United States
A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.
- Conditions
- Interventions
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT01916447
- Locations
- 🇺🇸
Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Chicago Clinical Site, Chicago, Illinois, United States
🇺🇸Los Angeles Clinical Site, Los Angeles, California, United States
A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2013-07-22
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT01904253
- Locations
- 🇯🇵
National Cancer Center Hospital East, Chiba, Japan
🇮🇹Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Italy
🇯🇵Hyogo Cancer Center, Hyogo, Japan
Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI
- Conditions
- Interventions
- First Posted Date
- 2013-06-11
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT01874522
- Locations
- 🇺🇸
Scottsdale Healthcare, Scottsdale, Arizona, United States
Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT01867866
- Locations
- 🇺🇸
South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT01867879
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
- First Posted Date
- 2012-05-30
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 800
- Registration Number
- NCT01607957
- Locations
- 🇺🇸
San Jose Medical Group, San Jose, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Jefferson City Medical Group, Jefferson City, Missouri, United States